Argenx Se (ARGX) has released an update.
Argenx SE, an immunology-focused biotech firm, will present its ambitious ‘Vision 2030’ to bring breakthrough science to 50,000 patients on R&D Day, July 16, 2024. The company plans to reveal Phase 2 data supporting Phase 3 development for treatments in Sjogren’s disease and multifocal motor neuropathy, as well as introduce new pipeline candidates. Additionally, Argenx has decided to discontinue the development of efgartigimod in PC-POTS following Phase 2 results, opting to focus on its active clinical trials and novel antibody-based therapeutics.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.